An observational study at MD Anderson Cancer Center designed to evaluate quality of life in women who received breast cancer treatment while pregnant has been terminated. The trial's early closure leaves a gap in prospective data on this clinically complex population.
An observational study registered at MD Anderson Cancer Center (NCT07191496) aimed to characterize quality-of-life outcomes in breast cancer survivors who underwent oncologic treatment during pregnancy has been listed as terminated. The study intended to use questionnaire-based assessments to capture the physical, psychological, and functional burden experienced by this distinct survivor cohort.
Breast cancer diagnosed during pregnancy—a condition sometimes referred to as pregnancy-associated breast cancer—presents unique clinical and ethical challenges, requiring oncologists to balance maternal treatment efficacy against fetal safety. Systemic therapies, including certain chemotherapy regimens, may be administered during the second and third trimesters under carefully managed protocols, yet the downstream impact on maternal quality of life in survivorship remains poorly characterized.
The premature termination of this trial means that prospective, structured quality-of-life data for this population will not be generated through this protocol. Clinicians managing pregnant patients with breast cancer or counseling survivors from this group will continue to rely on limited retrospective data and case series. The reasons for termination were not specified in the registry record, and the extent of enrollment prior to closure is not publicly documented.
Key points
- Observational study NCT07191496 at MD Anderson Cancer Center, targeting quality-of-life assessment in breast cancer survivors treated during pregnancy, has been terminated.
- The study planned to use validated questionnaires to evaluate survivorship outcomes in women with pregnancy-associated breast cancer.
- Termination leaves a prospective data gap for a clinically underserved population facing dual oncologic and obstetric complexity.
- Reasons for early termination and enrollment figures are not disclosed in the ClinicalTrials.gov registry entry.
- Clinicians will continue to lack robust prospective quality-of-life benchmarks for this cohort pending alternative research efforts.
Why it matters
Pregnancy-associated breast cancer is a rare but high-stakes clinical scenario with limited survivorship outcome data; the termination of this observational trial underscores the ongoing difficulty of conducting prospective research in this vulnerable population. Oncologists and obstetricians co-managing these cases have few evidence-based quality-of-life frameworks to guide survivorship counseling.